Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

595
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
595
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

545
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
545
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

544
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
544
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

398
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

427
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
427
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

537
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UNICORN During Transcatheter Aortic Valve Replacement in Native and Bioprosthetic Aortic Valves: A Multicenter Study.

JACC. Cardiovascular interventions·2026
Same author

Balloon-Assisted Translocation of the Mitral Anterior Leaflet to Prevent Outflow Tract Obstruction During TMVR: The BATMAN Registry.

JACC. Cardiovascular interventions·2026
Same author

Leaflet Modification to Mitigate Coronary Obstruction Risk During TAVR: Results From the LOFTER-TAVR Registry.

JACC. Cardiovascular interventions·2026
Same author

Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation Post-Left Ventricular Assist Device.

JACC. Case reports·2026
Same author

Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.

Circulation. Cardiovascular interventions·2026
Same author

Mechanical Cardiocirculatory Support Devices in Valvular Cardiogenic Shock.

Interventional cardiology clinics·2026

Related Experiment Video

Updated: Mar 24, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.2K

Advances in dual therapy stenting.

Gennaro Giustino1, Michela Faggioni, Roxana Mehran

  • 1Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine, Mount Sinai, New York, NY, USA - roxana.mehran@mountsinai.org.

Minerva Cardioangiologica
|March 3, 2016
PubMed
Summary

Dual therapy stenting combines drug elution with endothelial progenitor cell capture to reduce restenosis and thrombosis. This innovative approach may offer a safer option for patients needing percutaneous coronary intervention, especially those at high bleeding risk.

More Related Videos

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.1K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Related Experiment Videos

Last Updated: Mar 24, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.2K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.1K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.5K

Area of Science:

  • Interventional cardiovascular medicine
  • Biomaterials science
  • Vascular biology

Background:

  • Drug-eluting stents (DES) reduced restenosis but posed thrombosis risks due to incomplete endothelialization.
  • Second-generation DES improved safety but limitations persist.
  • Neointimal hyperplasia remains a challenge in percutaneous coronary intervention.

Purpose of the Study:

  • To review the rationale, preclinical, and clinical studies of dual therapy stenting.
  • To highlight the potential of dual therapy stenting in preventing stent-related complications.
  • To explore its application in high-risk bleeding patients.

Main Methods:

  • Review of existing literature on dual therapy stenting.
  • Analysis of preclinical data on stent endothelialization and drug elution.
  • Evaluation of clinical trial outcomes related to dual therapy stents.

Main Results:

  • Dual therapy stenting aims to accelerate endothelialization via endothelial progenitor cell capture.
  • It combines antiproliferative drug elution with enhanced endothelial healing.
  • This approach may mitigate risks of late and very-late stent thrombosis.

Conclusions:

  • Dual therapy stenting presents a novel strategy to improve DES safety and efficacy.
  • Faster endothelialization could reduce thrombotic events and allow shorter dual antiplatelet therapy.
  • This technology offers a promising alternative for complex patient populations.